Mayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium 2018
October 26-27, 2018

Program Schedule

Friday, October 26, 2018

7:30 a.m. Registration & Continental Breakfast

8:00 Welcome Announcements
Mitesh J. Borad, M.D., Mayo Clinic, Phoenix, Arizona

GLOBAL BURDEN OF HEPATO-BILIARY CANCER, IMAGING AND DIAGNOSTIC CHALLENGES
Moderator: Marcela A. Salomao, M.D., Mayo Clinic, Scottsdale, Arizona

8:15 Gallbladder Cancer in Chile: Perspectives from a High Incidence Region
Jorge Gallardo, M.D., SLAGO, Chile

8:35 HCC in Sub-Saharan Africa: Challenges in Diagnosis and Management
Col. Sosthene Somda, M.D., National Hospital Yalgado Ouedraogo, Burkina Faso, West Africa

9:00 Diagnosis and Assessment of Treatment of Response in Hepato-Biliary Cancers
Alvin C. Silva, M.D., Mayo Clinic, Phoenix, Arizona

9:20 Pathological Challenges in Hepato-Biliary Cancers
Marcela A. Salomao, M.D., Mayo Clinic, Scottsdale, Arizona

9:40 Rare Cancers of the Hepato-Biliary System
Michael S. Torbenson, M.D., Mayo Clinic, Rochester, Minnesota

10:00 Panel and Q&A

10:20 Break

THERAPEUTIC INNOVATIONS IN THE MANAGEMENT OF HEPATO-BILIARY CANCERS
Moderator: Amit K. Mathur, M.D., Mayo Clinic, Phoenix, Arizona

10:45 Transplant Beyond Milan Criteria in HCC
Linda L. Wong, M.D., University of Hawaii, Honolulu, Hawaii

11:05 Surgical Management of HCC
Adyr A. Moss, M.D., Mayo Clinic, Phoenix, Arizona
**CONTROVERSIES AND CONUNDRUMS IN HEPATO-BILIARY CANCER MANAGEMENT**  
**Moderator:** Daniel H. Ahn, D.O., *Mayo Clinic, Scottsdale, Arizona*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td><strong>The Case for Radio-Embolization in Management of HCC</strong></td>
<td>Beau Toskich, M.D.</td>
<td><em>Mayo Clinic, Jacksonville, Florida</em></td>
</tr>
<tr>
<td>1:45</td>
<td><strong>Radio-Embolization is Not Indicated in Management of HCC</strong></td>
<td>Kabir Mody, M.D.</td>
<td><em>Mayo Clinic, Jacksonville, Florida</em></td>
</tr>
<tr>
<td>2:00</td>
<td><strong>There is a Role for Adjuvant Therapy in Biliary Cancers – FOR</strong></td>
<td>Rachna T. Shroff, M.D., M.S.</td>
<td><em>University of Arizona, Tucson, Arizona</em></td>
</tr>
<tr>
<td>2:15</td>
<td><strong>There is Not a Role for Adjuvant Therapy in Biliary Cancers – AGAINST</strong></td>
<td>Milind Javle, M.D.</td>
<td><em>MD Anderson Cancer Center, Houston, Texas</em></td>
</tr>
<tr>
<td>2:30</td>
<td><strong>Panel and Q&amp;A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Pancreatic Sessions – Select One**  
*(Concurrent Breakouts in separate rooms)*

**BREAKOUT A: PANCREATIC CANCER: ACCELERATING PROGRESS FROM BENCH TO BEDSIDE**  
*MEETING ROOM: GREENWAY*

**Moderator:** Martin E. Fernandez-Zapico, M.D., *Mayo Clinic, Rochester, Minnesota*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00</td>
<td>Microbiome: Not Just Gut Bacteria, but Affects Treatment Response</td>
<td>Christian Jobin, Ph.D., <em>University of Florida, Gainesville, Florida</em></td>
</tr>
<tr>
<td>3:30</td>
<td>An Unexpected Journey – GSK-3B at the Crossroads of the DNA Damage Response and Chemosensitization in Pancreatic Cancer</td>
<td>Daniel D. Billadeau, Ph.D., <em>Mayo Clinic, Rochester, Minnesota</em></td>
</tr>
<tr>
<td>4:00</td>
<td>Stroma and Stem Cells: Are they Relevant?</td>
<td>Michael T. Barrett, Ph.D., <em>Mayo Clinic, Scottsdale, Arizona</em></td>
</tr>
<tr>
<td>4:30</td>
<td>Panel and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

**BREAKOUT B: HEPATO-BILIARY CANCER: ACCELERATING PROGRESS FROM BENCH TO BEDSIDE**  
*MEETING ROOM: HERBERGER 4/5 A/B*

**Moderator:** Mitesh J. Borad, M.D., *Mayo Clinic, Phoenix, Arizona*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00</td>
<td>Tissue-Specific Features of the Liver that Influence HCC Development</td>
<td>Hao Zhu, M.D., <em>UT Southwestern, Dallas, Texas</em></td>
</tr>
<tr>
<td>3:20</td>
<td>Genomic Profiling of Hepato-Biliary Cancers</td>
<td>Lewis R. Roberts, M.B., Ch.B., Ph.D., <em>Mayo Clinic, Rochester, Minnesota</em></td>
</tr>
<tr>
<td>3:40</td>
<td>Animal Models in HCC Research</td>
<td>Dan G. Duda, Ph.D., D.M.D., <em>Massachusetts General Hospital, Boston, Massachusetts</em></td>
</tr>
<tr>
<td>4:00</td>
<td>Animal Models in Cholangiocarcinoma Research</td>
<td>Lawrence Kwong, Ph.D., <em>MD Anderson Cancer Center, Houston, Texas</em></td>
</tr>
<tr>
<td>4:30</td>
<td>Panel and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
Friday, October 26, 2018 (continued)

5:00  Keynote Speaker: Introduction
Daniel D. Von Hoff, M.D., F.A.C.P., Translational Genomics Research Institute (TGen); Virginia G. Piper Cancer Center at HonorHealth, Scottsdale, Arizona

5:15  Pancreatic Cancer Biology and Medicine
David A. Tuveson, M.D., Ph.D., Cold Springs Laboratory, Cold Springs Harbor, New York

6:00  Conclusion and Adjourn
Mitesh J. Borad, M.D., Mayo Clinic, Phoenix, Arizona

6:00  Welcome Reception
Saturday, October 27, 2018

7:45 a.m.  Breakfast

8:15  Welcome Announcements
Tanios S. Bekaii-Saab, M.D., Mayo Clinic, Phoenix, Arizona

MANAGEMENT OF THE EARLY STAGE PATIENT
Moderator: Adyr A. Moss, M.D., Mayo Clinic, Phoenix, Arizona

8:30  Case History
Kumar Sandrasegaran, M.D., Mayo Clinic, Phoenix, Arizona

8:45  Interventional and Diagnostic Endoscopy
Douglas O. Faigel, M.D., Mayo Clinic, Scottsdale, Arizona

9:05  When Should the Surgeon Operate?
Eric Nakakura, M.D., Ph.D., UCSF, San Francisco, California

9:35  Adjuvant Therapy after Resection
Margaret A. Tempero, M.D., UCSF, San Francisco, California

10:05  Q&A

10:20  Break

MANAGEMENT OF THE NON-METASTATIC ADVANCED PATIENT
Moderator: Jonathan B. Ashman, M.D., Ph.D., Mayo Clinic, Phoenix, Arizona

10:40  Chemotherapy: Which Regimen and How Long?
Jordan D. Berlin, M.D., Vanderbilt – Ingram Cancer Center, Nashville, Tennessee

11:10  Pushing the Limits of Resectability
Mark J. Truty, M.D., M.S., Mayo Clinic, Rochester, Minnesota

11:40  Viewpoint: High Dose Radiation Can Improve Pancreatic Cancer Survival
Parag J. Parikh, M.D., B.S.E., Washington University School of Medicine, St. Louis, Missouri

12:10 p.m.  Q&A

12:30  Lunch

MANAGEMENT OF THE PATIENT WITH ADVANCED DISEASE
Moderator: Wen Wee Ma, M.B.B.S., Mayo Clinic, Rochester, Minnesota

1:30  Case History
Wen Wee Ma, M.B.B.S., Mayo Clinic, Rochester, Minnesota
1:45  Chemotherapy Regimens: Is More and Longer Better?  
    Zev Wainberg, M.D., UCLA Health, Los Angeles, California

2:15  Use of Molecular Profiling to Guide Therapy  
    Diane M. Simeone, M.D., NYU Langone Medical Center, New York, New York

2:45  Q&A

3:00  Break

PNET AND NEW APPROACHES  
Moderator: Daniel H. Ahn, D.O., Mayo Clinic, Scottsdale, Arizona

3:30  How Do I Manage Pancreatic Neuroendocrine Cancers  
    Thorvardur R. Halldanarson, M.D., Mayo Clinic, Rochester, Minnesota

4:00  New Agents and Combinations in Late Stage Trials  
    Colin D. Weekes, M.D., Ph.D., Massachusetts General Hospital, Boston, Massachusetts

4:30  Conclusion and Adjourn  
    Tanios S. Bekaii-Saab, M.D., Mayo Clinic, Phoenix, Arizona